US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Imago BioSciences, Inc. - Common stock (NQ:IMGO)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 10, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Imago BioSciences, Inc. - Common stock

News headline image
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
IMAGO BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Imago BioSciences, Inc. - IMGO
From Kahn Swick & Foti, LLC
Via Business Wire
TC BioPharm Ltd ($TCBP) leads fight against Acute myeloid leukemia with its cell therapy product OmnImmune
Via AB Newswire
Topics Death Economy Stocks
News headline image
Imago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion
Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
News headline image
IMGO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Imago BioSciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Merck to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
News headline image
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021
From Imago BioSciences
Via Business Wire
News headline image
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021
From Imago BioSciences, Inc.
Via Business Wire
News headline image
Imago BioSciences Appoints Laurie Keating to Board of Directors
From ​Imago BioSciences, Inc.
Via Business Wire
News headline image
Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition
From Imago BioSciences, Inc.
Via Business Wire
News headline image
Imago BioSciences Announces Its Addition to the Russell 2000® Index
From ​Imago BioSciences, Inc.
Via Business Wire
News headline image
Imago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business Updates
From Imago BioSciences, Inc.
Via Business Wire
News headline image
Imago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential Thrombocythemia
From Imago BioSciences
Via Business Wire
News headline image
Imago BioSciences, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
From Imago BioSciences, Inc.
Via Business Wire
News headline image
Imago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public Offering
From Imago BioSciences, Inc.
Via Business Wire
News headline image
Imago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock
From Imago BioSciences, Inc.
Via Business Wire